Drug details

Nerlynx (neratinib tablets)

type of Antineoplastic Tyrosine Kinase Inhibitors, Antineoplastics EGFR Inhibitors, Antineoplastics, Anti-HER2

Nerlynx (neratinib) tablets are a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• itching,
• dark urine,
• clay-colored stools, and
• yellowing of the skin or eyes (jaundice)
• vomiting,
• fever,
• shortness of breath,
• tiredness,
• little or no urination,
• swelling in your feet or ankles,
• right-sided upper stomach pain,
• pain or burning when you urinate,
• severe or ongoing diarrhea,

The following drugs are related to Nerlynx, either as a replacement or used together:

• Piqray (alpelisib tablets)
• Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection, for subcutaneous use)
• Margenza (margetuximab-cmkb injection, for intravenous use)